0001193125-26-212064
SEC filingRevelation Biosciences reported Q1 2026 net loss of $3.0M, cash of $14.1M, and FDA agreement on a Phase 2/3 study for Gemini in acute kidney injury.
Revelation Biosciences reported a net loss of $3.0 million for Q1 2026, compared to a net loss of $2.1 million in the same period last year. The increased loss was driven by higher operating expenses: R&D expenses rose to $1.38 million from $0.86 million, reflecting progress on the Gemini clinical program, and G&A expenses increased to $1.72 million from $1.24 million, likely due to higher headcount and professional fees. The company ended the quarter with $14.1 million in cash, up from $10.7 million at year-end 2025, primarily due to $6.7 million in net proceeds from a January 2026 warrant inducement. Cash used in operations was $3.2 million, slightly higher than $2.8 million in Q1 2025. Management stated that current cash is sufficient to fund operations through Q1 2027. A key corporate highlight was the FDA agreement on a single adaptive Phase 2/3 study for Gemini in acute kidney injury, which could accelerate the path to approval. The weighted-average share count increased dramatically to 3.2 million from 80,943, reflecting the warrant exercise and share issuances, which diluted EPS but also strengthened the balance sheet. The company also presented positive data from the PRIME Study at a nephrology conference. Overall, the quarter reflects continued investment in clinical development with a strengthened cash position and a clear regulatory milestone.